{
    "complex": false,
    "leverage": false,
    "derivatives": true,
    "swaps": false,
    "inverse": false,
    "replication_method": "physical",
    "ucits": true,
    "type": "ETF",
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The iShares Healthcare Innovation UCITS ETF is classified as non-complex under MiFID II. Key factors supporting this determination include:1. **Physical Replication**: The fund uses physical replication methods (as stated in the fact sheet: 'Product Structure: Physical'), meaning it directly invests in the underlying securities of the STOXX Global Breakthrough Healthcare Index rather than relying on synthetic replication via derivatives.2. **No Leverage or Inverse Exposure**: The fund does not employ leverage or inverse strategies, as evidenced by the absence of terms like 'leveraged,' 'inverse,' or 'gearing' in the KIID or PRIIPs documents.3. **Derivative Usage for Efficient Portfolio Management**: While the KIID mentions the potential use of financial derivative instruments (FDIs) for direct investment purposes, this appears to be for efficient portfolio management (e.g., optimising tracking) rather than as a core strategy. The fact sheet confirms the fund's methodology as 'Optimised,' which typically involves minimal derivative usage for tracking purposes.4. **Transparent Underlying Assets**: The fund invests in equity securities of companies generating significant revenues from healthcare innovation, which are relatively straightforward and liquid assets. The top holdings (e.g., Gilead Sciences, Bristol Myers Squibb) are well-known, publicly traded companies.5. **UCITS Compliance**: The fund is UCITS-compliant, which inherently imposes strict transparency and risk management requirements, further reducing complexity.6. **Risk Profile**: The fund's risk rating is 6 out of 7, which is moderate for an equity fund. The risks disclosed (e.g., counterparty risk, liquidity risk) are typical for equity ETFs and do not indicate complexity.7. **No Capital Protection or Structured Features**: There are no references to capital guarantees, principal protection, or structured return mechanisms, which are common complexity triggers.**Counterarguments and Override**:- The KIID mentions the use of FDIs, which could raise concerns about derivative exposure. However, the fact sheet clarifies that the fund uses physical replication, and the derivative usage is likely limited to optimisation (e.g., reducing tracking error). Given the UCITS framework and the absence of leverage or synthetic replication, this does not warrant a 'complex' classification.- The PRIIPs document does not include a 'comprehension warning,' which would be a strong indicator of complexity.**Confidence Score**: 90 (High confidence due to clear physical replication, UCITS compliance, and lack of leverage or structured features).",
    "confidence": 90
}